For research and educational purposes only. Not intended for human consumption.
LL-37
Well Researched- •68% chronic ulcer area reduction
- •Biofilm disruption mechanism confirmed
- •Plasma t½ ~30 min (rapid clearance)
Human Cathelicidin | Antimicrobial & Immune Support
Overview
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses and promoting wound healing.
Key Benefits
Direct wound healing acceleration, local antimicrobial protection, enhanced tissue regeneration, biofilm disruption.
Mechanism of Action
Topical application provides direct access to wound sites, promoting keratinocyte migration, angiogenesis, and antimicrobial protection without systemic exposure.
Molecular Information
Pharmacokinetics
Research Indications
Chronic Venous Leg Ulcers
Clinical trials show 68% ulcer area reduction with 0.5 mg/mL concentration.
Diabetic Foot Ulcers
Enhanced granulation tissue formation and healing rate in clinical studies.
Pressure Ulcers
Chitosan hydrogel delivery systems demonstrate accelerated healing in animal models.
Research Protocols
Disclaimer: LL-37 is primarily used topically for wound healing. These protocols are based on clinical research. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Chronic Venous Ulcers | 0.5 mg/mL | Twice weekly | Topical gel application |
| Diabetic Foot Ulcers | 0.5-1.6 mg/mL | Daily application | Topical cream |
| Acute Wound Healing | 1.6 mg/mL | Once daily | Topical gel or cream |
| Pressure Ulcer Treatment | 0.5-1.0 mg/mL | Twice daily | Hydrogel delivery system |
| Burn Wound Care | 1.0 mg/mL | Once to twice daily | Topical gel application |
Timing: Apply after wound cleaning. Can be used with standard dressings. Monitor wound healing progress.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Ensure wound area is properly cleaned and debrided if necessary
Apply thin layer of LL-37 gel or cream directly to wound surface
Cover with appropriate sterile dressing if recommended
Change dressing according to clinical protocol (typically daily to twice weekly)
Monitor wound healing progress and adjust application frequency as needed
Document wound measurements and healing progression
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Sterile Formulation
Topical LL-37 should be sterile with preservatives appropriate for wound care.
Appropriate Gel Base
Compatible gel or cream base that doesn't interfere with peptide activity.
Proper Concentration
Clinical-grade concentrations (0.5-1.6 mg/mL) with verified potency.
Cold Storage Maintenance
Maintained at 2-8°C throughout storage and transport.
Contaminated Products
Any signs of microbial contamination or non-sterile preparation.
Improper pH Formulation
pH outside physiological range that could irritate wound tissue.
What to Expect
- •Week 1-2: Reduced bacterial load, initial wound bed preparation
- •Week 2-4: Increased granulation tissue formation, epithelial migration
- •Week 4-6: Significant wound size reduction, improved healing quality
- •Week 6-8: Continued healing progress toward complete wound closure
Side Effects & Safety
Side Effects
- •Use only on clean, debrided wounds as directed by healthcare provider
- •Monitor for signs of wound infection or delayed healing
- •Discontinue if signs of hypersensitivity or allergic reactions develop
- •Use sterile technique for application to prevent contamination
When to Stop
- •Signs of allergic reaction
- •Worsening wound infection
- •Severe skin irritation
- •As directed by physician
- •Upon wound closure
References
3 StudiesMRSA Biofilm Eradication (2019)
In vitro | 10-100 μM | 60 minutes | >4 log reduction in biofilm
CDC biofilm reactor study showing LL-37 achieved superior antimicrobial efficacy against Staphylococcus aureus biofilms compared to conventional antibiotics.
Venous Leg Ulcer Clinical Trial (2014)
Humans | 0.5-3.2 mg/mL topical | 4 weeks | 68% ulcer area reduction
First-in-man randomized, placebo-controlled trial in 34 participants with hard-to-heal venous leg ulcers. Demonstrated significant wound healing improvement.
View StudyMultidrug-Resistant Bacteria Study (2017)
Clinical isolates | 1-256 μg/mL MIC | Various pathogens | Broad-spectrum activity
Comprehensive antimicrobial profile study against human pathogens including antibiotic-resistant strains.
Quick Start Guide
Research Disclaimer
LL-37 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving LL-37 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of LL-37 for any purpose. Consult qualified professionals for any research applications.